New Patent ‘172 Issued
Existing ’087 Patent Stronger after Successful Reexamination
CLEVELAND, November 4 /PRNewswire/ – DATATRAK International, Inc. (OTCQX: DTRK), the leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced a strengthened IP portfolio, including:
- the recent issuance of another patent from the U.S. Patent and Trademark Office (USPTO): U.S. Patent No. 8,856,172, issued October 7, 2014; and
- the USPTO concluded reexamination proceedings for the ‘087 patent, confirming the validity of 47 claims covering various systems and methods for unifying data.
DATATRAK will continue to protect and expand its Intellectual Property, particularly those assets that reinforce its market differentiation. The ‘172 patent is the latest in the DATATRAK portfolio of patents supporting unifying data, including U.S. Patent No. 8,234,294, the newly reexamined U.S. Patent No. 7,464,087 and a pending patent application in this same family (U.S. Patent Appl. Ser. No. 14/489,871).
“DATATRAK has invested heavily in Research and Development efforts to better serve our clients and to maintain our competitive advantage. Similar to our clients, our IP assets are the essence of our market offerings. We will continue to protect our investments and IP,” said Laurence P. Birch, Chairman and CEO, DATATRAK. “This latest patent and the successful reexamination of the ‘087 patent extend the value of our unique solutions and are valuable assets in the DATATRAK technology portfolio. We are proud of our continued leadership in the eClinical industry.”
Join DATATRAK Thought Leaders:
Tweet: DATATRAK strengthens Data Unifier Patent Portfolio, #IP http://bit.ly/1uolOHD
About DATATRAK International, Inc.
DATATRAK International is a worldwide technology and services company delivering unified eClinical® solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via the DATATRAK Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE® software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Preclinical and Phase I – Phase IV drug and device studies in multiple languages throughout the world. DATATRAK is located in Cleveland, Ohio; Bryan, Texas; Cary (RTP), North Carolina, and the UK. For more information, visit http://www.datatrak.com.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements
are made based on management’s expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company’s report filed with the OTCQX Market on August 14, 2014 announcing its results for the second quarter period ending June 30, 2014. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
Contact: Dorothy Radke, Director Marketing, DATATRAK International, Inc., +1-440-443-0082